Background:Postpartum hemorrhage (PPH) is a leading cause of maternal morbi-mortality. While obstetric risk factors are well described, the impact of predelivery hematological and hemostatic biomarkers remains incompletely understood. Aims:In this systematic review, we aimed to summarize the available literature on the association between predelivery hemostatic biomarkers and PPH/severe PPH. Methods: Searching MEDLINE, EMBASE, and CENTRAL from inception to October 2022, we included observational studies on unselected pregnant women without bleeding disorder reporting on PPH and on predelivery hemostatic biomarkers. Two review authors independently performed title, abstract, and full text screening, upon which quantitative syntheses of studies reporting on the same hemostatic biomarker were conducted, calculating mean differences (MD) between women with PPH/severe PPH and controls. Results: Search of databases on October 18th, 2022 yielded 81 articles fitting our inclusion criteria. The heterogeneity between studies was considerable. With regard to PPH in general, the estimated average MD in investigated biomarkers (platelets, fibrinogen, hemoglobin, D-Dimer, aPTT, PT) were not statistically significant. Women who developed severe PPH had lower predelivery platelets than controls (MD = -26.0 G/L; 95%CI -35.8, -16.1), whereas differences in predelivery fibrinogen concentration (MD = -0.31 g/L; 95%CI -0.75, 0.13) and levels of Factor XIII (MD = -0.07 IU/mL; 95%CI -0.17, 0.04) or hemoglobin (-0.25 g/dL; 95%CI -4.36, 3.85) were not statistically significant in women with and without severe PPH. Conclusion: Predelivery platelet counts were on average lower in women with severe PPH compared with controls, suggesting the potential usefulness of this simple biomarker for predicting severe PPH.